These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 35579082)
1. CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR-33a/b to disinhibit PD-L1. Dong L; Huang J; Gao X; Du J; Wang Y; Zhao L Cancer Sci; 2022 Aug; 113(8):2888-2903. PubMed ID: 35579082 [TBL] [Abstract][Full Text] [Related]
2. MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1. Sun JR; Zhang X; Zhang Y Cell Mol Biol Lett; 2019; 24():68. PubMed ID: 31844419 [TBL] [Abstract][Full Text] [Related]
3. MiR-873/PD-L1 axis regulates the stemness of breast cancer cells. Gao L; Guo Q; Li X; Yang X; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Xi T; Zheng L EBioMedicine; 2019 Mar; 41():395-407. PubMed ID: 30803931 [TBL] [Abstract][Full Text] [Related]
4. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. Wang QM; Lian GY; Song Y; Huang YF; Gong Y Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647 [TBL] [Abstract][Full Text] [Related]
5. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells. Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928 [TBL] [Abstract][Full Text] [Related]
6. [Effect of Yuan J; Han H; Dong W; Wang RC; Hao HL Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):96-103. PubMed ID: 36765483 [TBL] [Abstract][Full Text] [Related]
7. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin. Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970 [TBL] [Abstract][Full Text] [Related]
8. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway. Wang S; Sun L Bioengineered; 2021 Dec; 12(1):8296-8308. PubMed ID: 34565287 [TBL] [Abstract][Full Text] [Related]
9. LncRNA NEAT1 regulate diffuse large B-cell lymphoma by targeting miR-495-3p/PD-L1 axis. Yuan J; Yang J; Wang R; Hao H; Li J Immunopharmacol Immunotoxicol; 2022 Jun; 44(3):429-436. PubMed ID: 35352617 [TBL] [Abstract][Full Text] [Related]
10. LncRNA PVT1 facilitates DLBCL development via miR-34b-5p/Foxp1 pathway. Tao S; Chen Y; Hu M; Xu L; Fu CB; Hao XB Mol Cell Biochem; 2022 Mar; 477(3):951-963. PubMed ID: 35098439 [TBL] [Abstract][Full Text] [Related]
11. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index. Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453 [TBL] [Abstract][Full Text] [Related]
12. CircRNA_OTUD7A upregulates FOXP1 expression to facilitate the progression of diffuse large B-cell lymphoma via acting as a sponge of miR-431-5p. Liu W; Lei L; Liu X; Ye S Genes Genomics; 2021 Jun; 43(6):653-667. PubMed ID: 33830472 [TBL] [Abstract][Full Text] [Related]
13. Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma. Wei T; Li M; Zhu Z; Xiong H; Shen H; Zhang H; Du Q; Li Q J Cancer Res Clin Oncol; 2021 Mar; 147(3):691-701. PubMed ID: 33389078 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma. Kwon HJ; Yang JM; Lee JO; Lee JS; Paik JH J Transl Med; 2018 Nov; 16(1):320. PubMed ID: 30458835 [TBL] [Abstract][Full Text] [Related]
15. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma. Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860 [TBL] [Abstract][Full Text] [Related]
16. HIF1A-AS2 Promotes the Proliferation and Metastasis of Gastric Cancer Cells Through miR-429/PD-L1 Axis. Mu L; Wang Y; Su H; Lin Y; Sui W; Yu X; Lv Z Dig Dis Sci; 2021 Dec; 66(12):4314-4325. PubMed ID: 33555514 [TBL] [Abstract][Full Text] [Related]
17. Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1. He B; Yan F; Wu C Biomed Pharmacother; 2018 Feb; 98():95-101. PubMed ID: 29247952 [TBL] [Abstract][Full Text] [Related]
18. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575 [TBL] [Abstract][Full Text] [Related]
19. LncRNA Xu YJ; Zhao JM; Ni XF; Wang W; Hu WW; Wu CP Epigenomics; 2021 Aug; 13(16):1281-1297. PubMed ID: 34523356 [TBL] [Abstract][Full Text] [Related]
20. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis. Zhao CX; Yan ZX; Wen JJ; Fu D; Xu PP; Wang L; Cheng S; Hu JD; Zhao WL Mol Cancer; 2021 Dec; 20(1):153. PubMed ID: 34852843 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]